Xeris Biopharma Holdings, Inc. (XERS): Operating Cash Flow
$28.63M
Year ended 2025-12-31
$56.61M
Trailing 12 months to 2026-06-30
| Period ended | Operating Cash Flow | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $28.63M | n/m | 2026-03-02, From 2025-01-01 |
| 2024-12-31 | -$36.98M | n/m | 2026-03-02, From 2024-01-01 |
| 2023-12-31 | -$47.02M | n/m | 2026-03-02, From 2023-01-01 |
| 2022-12-31 | -$102.89M | n/m | 2025-03-06, From 2022-01-01 |
| 2021-12-31 | -$95.53M | n/m | 2024-03-06, From 2021-01-01 |
| 2020-12-31 | -$80.56M | n/a | 2022-03-11, From 2020-01-01 |
Operating Cash Flow at similar companies
| Company | Year ended | Operating Cash Flow | Change YoY |
|---|---|---|---|
| Xeris Biopharma Holdings, Inc. (XERS) | 2025-12-31 | $28.63M | n/m |
| Ironwood Pharmaceuticals Inc (IRWD) | 2025-12-31 | $127.04M | +22.7% |
| Evolus, Inc. (EOLS) | 2025-12-31 | -$42.27M | n/m |
| CorMedix Inc. (CRMD) | 2025-12-31 | $175.05M | n/m |
| Harrow, Inc. (HROW) | 2025-12-31 | $43.86M | n/m |
| Vireo Growth Inc. (VREOF) | 2025-12-31 | $3.71M | n/m |
| Ligand Pharmaceuticals Inc (LGND) | 2025-12-31 | $49.36M | -49.1% |
| Arvinas, Inc. (ARVN) | 2025-12-31 | -$273.80M | n/m |
| Schrodinger, Inc. (SDGR) | 2025-12-31 | $13.90M | n/m |
Compare XERS, IRWD, EOLS, CRMD side by side · Screen every company in Pharmaceutical Preparations ↗